FTL 012
Alternative Names: FTL-012Latest Information Update: 10 Apr 2025
At a glance
- Originator Sound Biopharmaceuticals
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 02 Apr 2025 Preclinical trials in Unspecified in China (Parenteral) before April 2025 (Sound Biopharmaceuticals pipeline, April 2025)